Ligand-free state: ECL2 occupies the orthosteric pocket, enabling self-activation .
Gs-coupled state: Achieves full activation without external ligands, with a resolution of 3.32 Å .
Allosteric ligand-bound state: Reveals a side pocket for potential drug targeting .
Constitutive Activity: Unliganded GPR52 exhibits 83–87% maximal Gs activity but only 5–26% β-arrestin recruitment, indicating intrinsic signaling bias .
Pathway Modulation:
Schizophrenia: Agonists (e.g., FTBMT, HTL’149) suppress psychosis-related behaviors in rodents .
Huntington’s Disease: GPR52 knockout decreases mutant HTT accumulation and rescues behavioral deficits .
Triple-Negative Breast Cancer (TNBC): GPR52 loss promotes EMT and invasiveness via upregulated CREB1 pathways .
T Cells: Modulates cAMP levels but shows no impact on autoimmune encephalomyelitis (EAE) severity in knockout models .
| Compound | EC₅₀ (cAMP) | Bioavailability | Therapeutic Potential |
|---|---|---|---|
| FTBMT | 30 nM | High | Schizophrenia (Phase I trials) |
| EX5467 | Comparable | Moderate | Cognitive symptom rescue |
Orphan Status: Lack of confirmed endogenous ligands complicates mechanistic studies .
PTM Sensitivity: N-glycosylation at N20 is essential for receptor trafficking and activity .